-
2024-515603-19-00
4
Localized digestive Neuroendocrine Carcinomas
-
2024-511114-20-00
5
Craniopharyngioma
-
2024-514243-29-01
5
This is a prospective, French, multicenter, open-label, design, strati
-
2024-514848-88-00
4
Folliculitis decalvans
-
2024-514964-24-00
5
ulcerative colitis
-
2024-515663-59-00
5
intracerebral haemorrhage
-
2024-518138-10-00
4
Patients with DMMR and/or MSI metastatic colorectal cancer
-
2024-519753-11-00
4
Resectable borderline pancreatic adenocarcinoma
-
2025-521037-86-00
5
Immune system diseases
-
2025-521113-13-00
10
Early Parkinson’s Disease
-
2025-521199-80-00
4
Patients with previously untreated symptomatic chronic lymphocytic leu
-
2025-523172-23-00
1
Metastatic or locally advanced pancreatic cancer
-
2025-523674-16-00
5
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
-
2026-525643-32-00
6
ulcerative colitis
-
2025-521038-27-00
5
2026-06-23
Immune system diseases
-
2023-507485-10-00
9
2026-04-21
advanced breast cancer
-
2024-516163-88-00
11
2024-08-01
Acute ischemic stroke
-
2023-506581-31-00
1
2021-06-15
Acute Leukemia
-
2024-516796-33-00
4
2026-06-25
The medical condition studied in IMMUNO-BOS is Bronchiolitis obliteran
-
2025-525069-65-00
5
2026-06-24
Alcohol use disorder
-
2025-524297-42-00
5
2026-06-12
CLTI defined as Rutherford category 4 or 5
-
2024-518018-22-00
5
2026-06-11
staphylococcal endocarditis
-
2025-524573-16-00
6
2026-06-11
Crohn's disease
-
2025-521546-23-00
5
2026-04-21
Secondary progressive multiple sclerosis